AI Diagnostics: The End of the High-Cost Imaging Era

Executive Summary

• Ventripoint Diagnostics announced the doubling of its private placement to $1 million to fund commercialization, manufacturing scale‑up, regulatory submissions and operations.
• The company entered a partnership with Summit Sciences and Dana to develop ROI models and appointed David Swetlow as Chief Financial Officer.
• Ventripoint detailed its Device‑as‑a‑Service subscription model and a new hub‑and‑spoke collaboration with Nisg_a'a Valley Health Authority to deliver advanced cardiac imaging to remote Indigenous communities.

Key Details

• Private Placement: Original target $500,000 increased to $1 million; proceeds earmarked for commercialization activities, manufacturing scale‑up, continued regulatory submissions and operational requirements.
• Partnerships: Engaged Summit Sciences (consulting) and Dana to build advanced ROI models demonstrating cost savings for healthcare providers.
• Executive Appointment: David Swetlow appointed Chief Financial Officer; brings >15 years senior management experience from Sernova, Ondine, Protox, HealthPricer, QLT.
• Business Model Update: Introduced a Device‑as‑a‑Service (DaaS) subscription model aimed at shortening sales cycles and generating recurring revenue without large upfront capital expenditures for customers.
• Clinical Collaboration: Partnered with Nisg_a'a Valley Health Authority to implement a hub‑and‑spoke imaging solution, enabling remote ultrasound acquisition and centralized digital interpretation for Indigenous communities.
• Market Context: Cited upcoming CMS ACCESS Model (July 2026) that will create outcome‑aligned reimbursement pathways for AI‑enabled diagnostic platforms.

Notable Quotes

• “We are excited to partner with Dana and Summit Sciences to elevate our financial modeling capabilities,” said Hugh MacNaught, President & CEO of Ventripoint Diagnostics.
• “This initiative underscores our commitment to not only advancing cardiac care through technology but also ensuring that our solutions make strong economic sense for healthcare providers worldwide.” – Hugh MacNaught

Materiality Assessment: Non‑Material – Positive (the announcement provides positive corporate development information but does not constitute a material financial event).